Chrome Plugin Live! Redefine the way you read FinTwit š Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ONPPF
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
prnewswire.com
13 hours ago
Forecast
1566%2026-Revenue
22%2026-EPS
-122%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Relative Strength
ONPPF
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
OTC
Unprofitable
Unprofitable
Relative Strenght
Volume Buzz
2400%
Earning Acce
No
Dist 52w H.
0%Earnings Growth
YoY
Current
Estimates
Q4.22
N/A
-0.10
vsĀ -5.23
Q1.23
N/A
-0.08
vsĀ -1.31
Q2.23
N/A
-0.06
vsĀ -0.79
Q3.23
N/A
-0.04
vsĀ -1.00
Q4.23
N/A
-0.09
vsĀ -0.10
Q1.24
N/A
-0.05
vsĀ -0.08
Q2.24
N/A
-0.05
vsĀ -0.06
Q3.24
N/A
-0.04
vsĀ -0.04
Q4.24
N/A
-0.04
vsĀ -0.09
Q1.25
N/A
-0.28
vsĀ -0.05
Sales Growth
YoY
Current
Estimates
Q2.23
+197%
26MĀ vsĀ 8.8M
Q3.23
+393%
2.8MĀ vsĀ -958000
Q4.23
+853%
5.3MĀ vsĀ 560K
Q1.24
+351%
5.1MĀ vsĀ 1.1M
Q2.24
-69%
8.2MĀ vsĀ 26M
Q3.24
+203%
8.5MĀ vsĀ 2.8M
Q4.24
+86%
9.9MĀ vsĀ 5.3M
Q1.25
+162%
13.3MĀ vsĀ 5.1M
Q2.25
+202%
24.7MĀ vsĀ 8.2M
Q3.25
+331%
36.6MĀ vsĀ 8.5M
Return on Equity
QoQ
Q2.23
-32%
-0.32
vsĀ -0.31
Q3.23
-30%
-0.30
vsĀ -0.32
Q4.23
-143%
-1.43
vsĀ -0.30
Q1.24
+803%
8.03
vsĀ -1.43
Q2.24
-38%
-0.38
vsĀ 8.03
Q3.24
-44%
-0.44
vsĀ -0.38
Q4.24
-154%
-1.54
vsĀ -0.44
Q1.25
+1038%
10.38
vsĀ -1.54
Institutionnal Ownership
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How ONPPF compares to sector?